SG Americas Securities’s Acumen Pharmaceuticals ABOS Stock Holding History

SG Americas Securities’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-719,257	Closed	-$1.7M	–	3327
2026 Q1	$1.7M	Buy	719,257 +318,210	+79%	+$812K	﹤0.01%	1471
2025 Q4	$846K	Sell	401,047 -2,831	-0.7%	-$5.62K	﹤0.01%	2142
2025 Q3	$691K	Buy	+403,878	New	+$559K	﹤0.01%	1817
2025 Q2	–	Sell	-18,007	Closed	-$20K	–	2875
2025 Q1	$20K	Sell	18,007 -7,624	-30%	-$10.9K	﹤0.01%	3378
2024 Q4	$44K	Buy	25,631 +7,859	+44%	+$18.9K	﹤0.01%	2925
2024 Q3	$44K	Buy	+17,772	New	+$48.2K	﹤0.01%	3268
2024 Q2	–	Sell	-12,856	Closed	-$52K	–	2796
2024 Q1	$52K	Buy	+12,856	New	+$48.5K	﹤0.01%	2756

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SG Americas Securities's ABOS Position: Q2 2026 in Review

SG Americas Securities sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 719,257 shares — an estimated $1.7M sold.

SG Americas Securities first reported a position in ABOS in Q1 2024 and held it in 7 quarters. The position peaked at $1.7M in Q1 2026. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

SG Americas Securities reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
SG Americas Securities sold 719,257 Acumen Pharmaceuticals shares in Q2 2026, an estimated $1.7M.
SG Americas Securities first reported a position in Acumen Pharmaceuticals in Q1 2024 and held it in 7 quarters.
SG Americas Securities's Acumen Pharmaceuticals position peaked at $1.7M in Q1 2026.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.